The effect of remifentanil - thiopental sodium on cognitive impairment after electroconvulsive therapy

Comparison of the incidence and severity of cognitive impairment after electroconvulsive therapy under general anesthesia in the two groups with remifentanil- thiopental sodium thiopental - placebo in patients referred to ECT Center shafa of Rasht in 2013

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201306086280N2

Enrollment

120

Registered

2013-06-12

Start date

2013-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with psychiatric disorder. Mental and behavioural disorders due to psychoactive substance use,Schizophrenia, schizotypal and delusional disorders,Mood [affective] disorders

Interventions

Intervention 1: Intervention group: remifentanil 50 mic plus thiopental sodium. Intervention 2: Control group:normal salin plus thiopental sodium.

Treatment - Drugs

Intervention group: remifentanil 50 mic plus thiopental sodium

Control group:normal salin plus thiopental sodium

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with psychiatric disorders diagnosed by psychiatrists according to DSMIV-TR criteria; age between 18-60 years old; signing informed consent; ASA physical status I or II; ECT candidates for the first time. Exclusion criteria: emergency ECT; severe cognitive dysfunction prior to ECT; history of mental retardation; severe heart disease; history of previous ECT; ASA physical status III-IV; uncontrolled hypertension and needs to treat agitation after ECT.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Incidence of cognitive impairment after electroconvulsive therapy in general anesthesia with remifentani plus thiopental sudium. Timepoint: Before ECT, 5 hours and 24 hours after ECT. Method of measurement: By testing mini mental status exam (MMSE).;Severity of cognitive impairment after electroconvulsive therapy in general anesthesia with remifentani plus thiopental sudium. Timepoint: Before ECT, 5 hours and 24 hours after ECT. Method of measurement: By testing mini mental status exam (MMSE).	—

Measure

Time frame

Incidence of cognitive impairment after electroconvulsive therapy in general anesthesia with remifentani plus thiopental sudium. Timepoint: Before ECT, 5 hours and 24 hours after ECT. Method of measurement: By testing mini mental status exam (MMSE).;Severity of cognitive impairment after electroconvulsive therapy in general anesthesia with remifentani plus thiopental sudium. Timepoint: Before ECT, 5 hours and 24 hours after ECT. Method of measurement: By testing mini mental status exam (MMSE).

—

Secondary

Measure	Time frame
Blood pressure. Timepoint: Before induction of anesthesia, immediately after ECT, after entering the recovery. Method of measurement: By electronic sphygmomanometer in the ECT room.;Heart rate. Timepoint: Before induction of anesthesia, immediately after ECT, after entering the recovery. Method of measurement: By monitoring heart rate.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Haghighi

Anesthesiology and Critical Care Research Centre

mohaghighi@gums.ac.ir; vbuhosp@gmail.com+98 13 1321 0424

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026